Eisai, Inc. v. Sanofi Aventis U.S., LLC Case Brief
Complete case briefs with LSD+
Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: A dominant drug manufacturer’s market-share discount program was challenged by a competitor as de facto exclusive dealing. The court found the program lawful, reasoning that customers were not foreclosed from the market but simply chose the better economic deal, which is not an antitrust violation.
Legal Significance: This case clarifies that single-product loyalty discounts, even those offered by a monopolist, are generally lawful if they are above-cost and do not coerce customers. It distinguishes such discounts from the multi-product bundled rebates found unlawful in LePage’s Inc. v. 3M.
Eisai, Inc. v. Sanofi Aventis U.S., LLC Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Sanofi Aventis (Sanofi) manufactured Lovenox, a dominant anticoagulant drug with over 80% market share and a unique FDA-approved cardiology indication that competitors lacked. Eisai, Inc. (Eisai) sold a competing drug, Fragmin. Sanofi offered hospitals a discount program for Lovenox with two key features. First, it provided substantial discounts (up to 30%) to hospitals that purchased at least 75% of their anticoagulant drugs from Sanofi; below this threshold, the discount was only 1%. Second, a formulary access clause required participating hospitals not to restrict access to Lovenox more than its competitors. Hospitals were not contractually obligated to meet the 75% threshold and could terminate the contract with 30 days’ notice. The only penalty for non-compliance was the loss of the higher discount. Eisai sued, alleging this program constituted a de facto exclusive dealing arrangement that unlawfully maintained Sanofi’s monopoly. Eisai’s expert argued Sanofi bundled hospitals’ “incontestable demand” for Lovenox (due to its unique indication) with their “contestable demand,” effectively foreclosing competitors.
Court Holding & Legal Precedent
Issue: Did a dominant pharmaceutical company’s program of market-share-based discounts and formulary access requirements for a single product constitute an unlawful exclusive dealing arrangement that substantially lessened competition under the rule of reason?
No. The court affirmed summary judgment for Sanofi, holding that Eisai failed Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
IRAC Legal Analysis
About IRAC analysis
IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.
Legal Issue
Did a dominant pharmaceutical company’s program of market-share-based discounts and formulary access requirements for a single product constitute an unlawful exclusive dealing arrangement that substantially lessened competition under the rule of reason?
Conclusion
The decision reinforces the high bar for proving de facto exclusive dealing, Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Legal Rule
An exclusive dealing arrangement violates the antitrust laws under the rule of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaeca
Legal Analysis
The court analyzed Sanofi's conduct under the rule of reason as a Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia de
Flash-to-Full Case Opinions
Flash Summary
- Holding: Affirmed summary judgment for defendant Sanofi; its market-share discount program